Table 2.
The association between pre-operative expression of exosomal peptides and metastasis of lymph nodes.
| Variable | LNs Metas | p-Value | |
|---|---|---|---|
| Yes (n = 8) | No (n = 13) | ||
| Pre-op exosome expression | |||
| UEx Thyroglobulin | 1.08 (0.67–1.62) | 2.21 (0.91–4.13) | 0.33 b |
| UEx Galectin-3 | 0.69 (0.57–2.39) | 1.28 (0.72–2.28) | 0.46 b |
| UEx Transketolase | 1.64 (0.45–13.36) | 0.51 (0.19–1.27) | 0.14 b |
| UEx Calprotectin A8 | 10.10 (1.42–27.68) | 42.00 (3.05–71.60) | 0.17 b |
| UEx Calprotectin A9(2) * | 38.28 (17.24–252.80) | 22.08 (4.88–67.58) | 0.49 b |
| UEx Calprotectin A9(13) * | 19.68 (7.54–87.20) | 5.20 (5.12–16.08) | 0.14 b |
| UEx Annexin-2 | 55.20 (25.60–165.60) | 40.81 (19.90–119.59) | 0.49 b |
| UEx Afamin | 0.60 (0.25–0.80) | 0.31 (0.00–0.70) | 0.58 b |
| UEx Angiopoietin-1 | 0.95 (0.55–1.98) | 0.00 (0.00–1.02) | 0.09 b |
| UEx Keratin-19 | 0.79 (0.56–1.45) | 0.69 (0.53–1.54) | 1.00 b |
| UEx TIMP (5) * | 2.73 (1.67–4.11) | 0.95 (0.00–1.42) | 0.01 b |
| UEx TIMP (14) * | 1.63 (0.33–6.38) | 0.68 (0.19–1.26) | 0.31 b |
| UEx Keratin 8 (8) * | 0.48 (0.23–1.07) | 0.42 (0.23–0.80) | 0.61 b |
| UEx Keratin 8 (17) * | 1.34 ± 0.92 | 0.94 ± 0.63 | 0.25 a |
| Demography | |||
| Gender | 0.79 c | ||
| Male | 1 (33.33%) | 2 (66.67%) | |
| Female | 7 (38.89%) | 11 (61.11%) | |
| Age (Year) | 49.75 ± 13.77 | 52.23 ± 7.95 | 0.60 a |
| Hypertension | 0.62 c | ||
| Yes | 2 (50.00%) | 2 (50.00%) | |
| No | 6 (35.29%) | 11 (64.71%) | |
| Diabetes (type 2) | 1.00 c | ||
| Yes | 2 (40.00%) | 3 (60.00%) | |
| No | 6 (37.50%) | 10 (62.50%) | |
| Clinical parameters | |||
| TNM stage | 0.04 c | ||
| I | 5 (27.78%) | 13 (72.22%) | |
| II | 3 (100.00%) | 0 (0.00%) | |
| Tumor size (cm) | 1.30 (0.65–1.60) | 1.4 (0.9–1.7) | 0.69 b |
| Tumor multifocality | 0.13 c | ||
| Yes | 2 (100.00%) | 0 (0.00%) | |
| No | 6 (31.58%) | 13 (68.42%) | |
| Extrathyroid invasion | 1 (16.67%) | 5 (83.33%) | 0.34 c |
| I-131 treatment | 0.08 c | ||
| No | 1 (16.67%) | 5 (83.33%) | |
| 1 time | 4 (33.33%) | 8 (66.67%) | |
| 2 times | 3 (100.00%) | 0 (0.00%) | |
| I-131 cumulative dose | 87.5 (30–300 mCi) | 18.4 (0–30 mCi) | 0.02 b |
| ATA (IU/mL) | 0.39 c | ||
| <3 | 3 (27.27%) | 8 (72.73%) | |
| ≥3 | 5 (50.00%) | 5 (50.00%) | |
| TPO Ab (IU/mL) | 0.63 c | ||
| <3 | 5 (33.33%) | 10 (66.67%) | |
| ≥3 | 3 (50.00%) | 3 (50.00%) | |
| Post-operative TSH (IU/mL) | 36.46 (1.25–78.85) | 23.30 (0.96–111.00) | 0.97 b |
ATA: anti-thyroglobulin antibody; TPO Ab: thyroid peroxidase antibody. Note: There was 1 patient missing of UExTg and UEx Galectin-3. Bold value denotes statistically significant, p < 0.05. a Using Student’s t-test. b Using Wilcoxon rank sum test. c Using Fisher’s exact test. * The numbers in brackets are peptide No. (Table 3).